454 Life Sciences and Roche NimbleGen Announce Collaboration with Eli Lilly and SeqWright

Sequencing Genomic Regions Associated with Psychiatric Disease


454 Life Sciences, a Roche company, and Roche NimbleGen, both units of Roche Applied Science, have announced a collaboration with Eli Lilly and Company and SeqWright. The goal of this collaboration is to use genomic technologies to identify genetic variants possibly associated with various psychiatric diseases. SeqWright will utilize NimbleGen Sequence Capture technology to selectively enrich approximately 40 megabases of the human genome, which will then be comprehensively sequenced using 454 Life Sciences’ Genome Sequencer FLX System.

“Just a year ago, it would have been impossible to imagine how we could selectively sequence such a large portion of the human genome in such a fast and cost effective manner. Our goal at Lilly is to improve the outcomes of individual patients; increasing the speed at which we begin to understand the basis of disease is critical to improving those outcomes,” stated Brian Edmonds, Ph.D., Research Advisor, Global External Research and Development, Eli Lilly and Company. “We are participating in this collaboration as a way to better examine the root causes of various psychiatric diseases. If this project delivers as expected, we hope to identify new biomarkers or novel drug targets for future development of medicines to treat an array of psychiatric illnesses.”

Facts, background information, dossiers
  • Roche
  • psychiatric diseases
  • SeqWright
  • Lilly
  • human genome
  • Eli Lilly
  • biomarkers
More about Roche Diagnostics
More about Eli Lilly
  • News

    Chemists synthesize herbal alkaloid

    The club moss Lycopodium serratum is a creeping, flowerless plant used in homeopathic medicine to treat a wide variety of ailments. It contains a potent brew of alkaloids that have attracted considerable scientific and medical interest. However, the plant makes many of these compounds in ex ... more

    Sigma-Aldrich Joins RNAi Consortium

    Sigma-Aldrich Corporation has entered into an agreement with the Massachusetts Institute of Technology (MIT) to serve as a scientific collaborator and distribution partner of The RNAi Consortium (TRC). The consortium is based at The Broad Institute in Boston and is comprised of seven world- ... more

More about Roche
More about 454 Life Sciences
More about SeqWright
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE